We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Decision on BioMarin’s Duchenne Candidate Held Up
The FDA is postponing its decision on BioMarin’s investigational drug drisapersen for Duchenne muscular dystrophy, saying the review is still under way.